SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
-----------------------------
Date of report (Date of earliest event reported) June 22, 2001
-------------------------------
INSPIRE PHARMACEUTICALS, INC.
---------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-31135 04-3209022
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
4222 Emperor Boulevard, Suite 470, Durham, North Carolina 27703-8466
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (919) 941-9777
----------------------------
------------------------------------------------------------------------------
(Former Name or Former Address, If Changed Since Last Report)
Item 5. Other Events.
On June 27, 2001, Inspire Pharmaceuticals, Inc. and Allergan, Inc.
issued a press release regarding a collaboration for the development of two
novel compounds for the treatment of dry eye. A copy of the press release is
attached hereto as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit Number Description
- -------------- -----------
10.1* License, Development and Marketing Agreement between Inspire
Pharmaceuticals, Inc. and Allergan, Inc., dated as of June
22, 2001
99.1 Inspire Pharmaceuticals, Inc. and Allergan, Inc. press
release dated June 27, 2001
- --------------
*A request for confidential treatment has been submitted
with respect to this exhibit. The copy filed as an exhibit
omits the information subject to the request for
confidential treatment.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Inspire Pharmaceuticals, Inc.
By: /s/ Gregory J. Mossinghoff
----------------------------
Gregory J. Mossinghoff,
Senior Vice President and
Chief Business Officer
Dated: June 28, 2001
INDEX TO EXHIBITS
Exhibit Number Description
- -------------- -----------
10.1* License, Development and Marketing Agreement between Inspire
Pharmaceuticals, Inc. and Allergan, Inc., dated as of June
22, 2001
99.1 Inspire Pharmaceuticals, Inc. and Allergan, Inc. press
release dated June 27, 2001
- --------------
*A request for confidential treatment has been submitted
with respect to this exhibit. The copy filed as an exhibit
omits the information subject to the request for
confidential treatment.